Oppenheimer reiterates Nektar stock rating on alopecia trial data By Investing.com

Nektar Therapeutics reported 16-week extension data from its Phase 2b REZOLVE-AA alopecia areata study, with the combined SALT≤20 rate reaching about 28% at the 24µg/kg dose at Week 52. Oppenheimer reiterated an Outperform rating and $140 price target, saying the results support a longer 52-week Phase 3 induction design and strengthen rezpeg’s safety/efficacy profile versus JAK inhibitors. The stock has already surged nearly 789% over the past year and trades near its 52-week high of $86.95.

Analysis

NKTR is now trading less like a development-stage biotech and more like a probability-weighting contest on whether the market believes rezpeg can own the “clean efficacy” niche in alopecia areata. The key second-order effect is not just that the asset looks viable; it is that the bar for disappointment has moved much higher, so any future readout that looks merely good rather than clearly best-in-class can compress multiple turns quickly. In other words, upside from here is likely to be slower and more catalyst-dependent than the stock’s recent re-rating suggests.

The most important competitive dynamic is benchmark selection. If investors keep comparing rezpeg to low-dose JAKs, the narrative stays favorable; if the street shifts the frame toward broader, commercially relevant regimens and durability, the differentiation narrows and the premium multiple becomes harder to defend. For the category, a clean safety profile is the real wedge because it expands the addressable pool into patients and dermatologists who have been reluctant to use immunology-heavy alternatives.

The near-term risk is that the market has already priced in a lot of the Phase 3 setup. With the stock near highs and sell-side targets already aggressive, the next 1-3 months are more about execution risk, enrollment/design credibility, and the durability of the extension signal than about headline efficacy. Any delay, underpowered subgroup read, or safety noise would likely hit the stock harder than the initial good news lifted it.

The contrarian view is that this is still a single-asset story with commercial optionality, not a proven franchise, so the valuation is vulnerable to mean reversion if the pipeline breadth does not broaden fast enough. The right way to express upside may be via call structures into the next data window rather than outright stock, because implied expectations are now elevated and the risk/reward has shifted from asymmetric discovery to binary confirmation.

Key Decisions for Investors

• Trim or hedge existing NKTR longs into strength; the stock’s rerating leaves less room for a clean hold unless the next catalyst is within 4-8 weeks and clearly incremental.
• For tactical upside, buy NKTR call spreads out 1-3 months rather than stock; this preserves exposure to a follow-on data surprise while limiting damage if the market sells confirmation.
• If seeking relative value, pair long NKTR / short a higher-multiple, commercially noisier dermatology biotech basket over the next 1-2 quarters; the trade is based on NKTR’s cleaner safety narrative versus crowded efficacy-only peers.
• Set a catalyst-driven stop: if the next extension or Phase 3 design update fails to widen the efficacy gap or introduces tolerability questions, reduce exposure immediately as multiple compression could be swift.